Shanghai ZhenGe Biotech Raises USD100M in Series C Funding

January 12, 2022

Shanghai ZhenGe Biotech, a Shanghai, China-based company focused on providing a macromolecular biological drug CDMO service, raised USD100M in Series C funding.

The round was led by Goldman Sachs Asset Management and Sofina with participation from Novo Holdings A/S, Qiming Venture Capital, IDG Capital, LYFE Capital, Junxin Capital and Cowin Capital.…

This data comes from the ChinaPulse.com media intelligence and smart news insights monitoring platform.



Original URL: Click here to visit original article